BriaCell Therapeutics Files 10-Q for Q1 2025

TL;DR

BriaCell Therapeutics filed its Q1 2025 10-Q, showing financial updates.

AI Summary

BriaCell Therapeutics Corp. filed a 10-Q for the period ending October 31, 2024. The company, formerly known as Ansell Capital Corp., reported financial data for its fiscal quarters. Key financial statement details and balance sheet information as of July 31, 2023, and October 31, 2023, were included in the filing.

Why It Matters

This filing provides investors with an update on BriaCell Therapeutics' financial health and operational status for the first quarter of fiscal year 2025.

Risk Assessment

Risk Level: medium — As a biotechnology company, BriaCell Therapeutics faces inherent risks related to drug development, clinical trials, and regulatory approvals, which are not detailed in this specific filing but are typical for the industry.

Key Numbers

• 2024-10-31 — Reporting Period End Date (The 10-Q covers financial activities up to this date.)
• 2024-12-16 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
• 2023-07-31 — Previous Fiscal Year End (Provides a comparative point for financial analysis.)

Key Players & Entities

• BriaCell Therapeutics Corp. (company) — Filer of the 10-Q
• Ansell Capital Corp. (company) — Former name of BriaCell Therapeutics Corp.
• 20241031 (date) — End of the reporting period
• 20241216 (date) — Date of filing
• 001-40101 (other) — SEC File Number

FAQ

Filing Documents

• form10-q.htm (10-Q) — 1058KB
• ex31-1.htm (EX-31.1) — 17KB
• ex31-2.htm (EX-31.2) — 17KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-24-050214.txt ( ) — 5864KB
• bctx-20241031.xsd (EX-101.SCH) — 39KB
• bctx-20241031_cal.xml (EX-101.CAL) — 41KB
• bctx-20241031_def.xml (EX-101.DEF) — 231KB
• bctx-20241031_lab.xml (EX-101.LAB) — 312KB
• bctx-20241031_pre.xml (EX-101.PRE) — 279KB
• form10-q_htm.xml (XML) — 1104KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia, Canada 47-1099599 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 235 15 th Street, Suite 300 , West Vancouver , BC , V7T 2X1 (Address of Principal Executive Offices, including zip code) 604 - 921-1810 (Registrant's telephone number, including area code) N/A (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common shares, no par value BCTX The Nasdaq Stock Market LLC Warrants to purchase common shares, no par value BCTXW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No As of December 16, 2024, 44,204,161 common shares, no par value per share, of the Company were issued and outstanding. BRIACELL THERAPEUTICS CORP. Form 10-Q Table of Contents Page Part I. Financial Information 3 Item 1. Financial 3 Condensed Consolidated Balance Sheets as of October 31, 2024 (unaudited) and July 31, 2024 (audited) 3 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended October 31, 2024 4 Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) for the three months ended October 31, 2024 5 Unaudited Condensed Consolidated Statement of Cash Flows for the three months ended October 31, 2024 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3. Quantitative and Qualitative Disclosures Regarding Market Risk 22 Item 4. Controls and Procedures 23 Part II. Other Information 23 Item 1. Legal Proceedings 23 Item 1A. Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults Upon Senior Securities 23 Item 4. Mine Safety Disclosures 23 Item 5. Other Information 24 Item 6. Exhibits 24 Part III. Signatures 25 2 PART I-FINANCIAL INFORMATION Item 1. Financial Statements BRIACELL THERAPEUTICS CORP. CONDENSED CONSOLIDATED BALANCE SHEETS October 31, 2024 July 31, 2024 (Unaudited) (Audited) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 5,792,265 $ 862,089 Amounts receivable and prepaid expenses 2,426,830 2,791,765 Total current assets 8,219,095 3,653,854 NON-CURRENT ASSETS: Equity Investment in BC Therapeutics 421,975 418,490 Intangible assets, net 195,978 199,796 Property and equipment, net 365,336 388,175 Long term prepaid expenses 1,211,946 1,211,946 Total non-current assets 2,195,235 2,218,407 Total assets $ 10,414,330 $ 5,872,261 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Trade payables $ 4,233,968 $ 7,170,781 Accrued expenses and other payables 754,668 290,376 Total current liabilities 4,988,636 7,461,157 NON-CURRENT LIABILITIES: Warran

View Full Filing

View this 10-Q filing on SEC EDGAR